Agilent Technologies and the Toll of a Fine Business
What the business is
A laboratory instrument is a quiet toll bridge. The initial sale builds the crossing; consumables, reagents, and service contracts collect the recurring tolls.
Agilent Technologies sells analytical instruments, including liquid and gas chromatography and mass spectrometry systems, to pharmaceutical, biotechnology, chemical, food, environmental, and diagnostic laboratories. Consumables and services accounted for roughly half of FY2025 revenue of $6.95 billion, and that proportion has been rising. The result is a business that combines cyclical equipment purchases with steadier revenue from keeping laboratories supplied and their instruments running.
The primary moat is switching cost. Laboratories in regulated industries validate analytical methods around specific combinations of instruments and consumables. Replacing a vendor can require revalidation, bring additional expense, and introduce regulatory risk. Once an instrument is embedded in a laboratory workflow, the customer relationship can last much longer than the original sales process.
Intangible assets reinforce that position. Agilent has more than 3,500 patents, over 25 years of accumulated chromatography brand trust, and substantial regulatory expertise. These assets matter, but I regard them as supporting walls rather than the foundation. The core advantage is that changing laboratory systems is troublesome, while ordering another consumable or renewing service is comparatively easy.
The moat appears to be widening as the revenue mix moves toward recurring consumables and services. FY2025 service revenue grew 12% to $1.32 billion. More than 8PB of instrument telemetry data in 2025 also supports predictive maintenance and laboratory automation. Software can improve the service proposition, but physical measurement itself cannot simply be replaced by software.
There are vulnerabilities. New instrument sales remain cyclical, Chinese revenue is declining, tariffs could become a structural cost, and weaker pharmaceutical research spending could lengthen replacement cycles. The present chief executive’s capital-allocation record is also still short. A moat reduces competitive pressure; it does not abolish business risk, much as accountants have tried.
What the numbers say
Annual owner earnings were $1,184 million, broadly consistent with FY2025 free cash flow of roughly $1.2 billion. That supports the view that reported results are translating into cash without an obvious accounting distortion. The five-year average return on equity was 21.7%, with low variability, suggesting that retained capital has generally been used productively.
- Market cap (price-adjusted, 2026-10-07 close): $46.80 billion
- Owner-earnings yield (price-adjusted): 2.53%
- Share price (2026-10-07 close): $169.09
- 10-year Treasury: 5.28%
Those figures contain the valuation problem. A 2.53% owner-earnings yield against a 5.28% Treasury produces a spread of -2.75 percentage points. Agilent offers business quality and potential growth, but its current earning power provides substantially less yield than the government-bond benchmark.
The desk’s intrinsic-value range is $14.0–18.0 billion. The price-adjusted market capitalization is at a 234% premium to the low end and a 160% premium to the high end. That is not a disagreement caused by conservative rounding. The market price already gives considerable credit for durable customer relationships, recurring revenue, and future growth.
Capital allocation has generally been disciplined. Agilent authorized a $2 billion repurchase program in 2023, repurchased about $1.15 billion of stock in FY2024, and reduced repurchases to $425 million in FY2025 while pursuing acquisitions. The dividend payout has remained conservative. Acquisitions have usually been bolt-ons, including BioTek and the $950 million purchase of Biocare Medical completed in June 2026.
The record is not perfect. The $550 million Resolution Bioscience acquisition in 2021 was followed by contraction and was effectively a failure. It was not fatal, but a sensible ledger does not erase a mistake merely because the rest of the page looks tidy.
What Wall Street believes vs what I see
The recent headline mood is cautiously favorable. One headline says the recovery is real but so is the valuation. Another emphasizes third-quarter growth, expanding margins, and raised guidance. A third describes the second-quarter result as a solid beat while retaining a hold view. The shared conclusion is that operations are improving while valuation remains difficult.
I agree with the operational case. Regulatory switching costs, recurring service demand, and a growing consumables contribution make the recovery more credible than a simple rebound in equipment orders. Agilent also serves research, quality control, and compliance activities rather than depending on the success of a single clinical outcome.
Yet sound business analysis does not repeal arithmetic. A 2.53% owner-earnings yield against a 5.28% Treasury asks the investor to rely heavily on future growth before receiving much current earning power. The $46.80 billion market capitalization also sits far above the $14.0–18.0 billion intrinsic-value range.
I therefore see an admirable business priced as though ordinary disappointment has been placed under laboratory quarantine. Chinese weakness, persistent tariffs, slower research spending, or an expensive acquisition need not destroy the moat to make the valuation uncomfortable. At this price, remaining a good company may not be sufficient.
Verdict
Verdict: pass.
The 2.53% owner-earnings yield is below the 5.28% Treasury, so the shares fail the rubric’s watch threshold. The $46.80 billion market capitalization is also well above the $14.0–18.0 billion intrinsic-value range rather than at or below 70% of its low end, as the circle test requires. I would change the verdict if the price fell enough for the owner-earnings yield to clear the relevant rubric threshold, with circle additionally requiring the prescribed discount to intrinsic value.
This analysis is AI-generated, educational, and not investment advice. Figures may contain errors or be delayed. Disclaimer